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Abstract
Background: We present the electrophilic synthesis of [
18F]2b-carbomethoxy-3b-(4-fluoro)tropane [[
18F]CFT] and
the pharmacological specificity and selectivity of [
18F]CFT for monoamine transporters in the brain and peripheral
organs of rats. The human radiation dose is extrapolated from the animal data.
Methods: [
18F]CFT was synthesized by electrophilic fluorination of a stannylated precursor by using post-target-
produced [
18F]F2 as a fluorinating agent. The ex vivo
18F-activity biodistribution of [
18F]CFT in the brain of rats was
studied by autoradiography. The binding of [
18F]CFT to the monoamine transporters was studied using in vivo
blocking experiments with dopamine transporter [DAT], norepinephrine transporter [NET], or serotonin transporter
[SERT] inhibitors. In vivo animal positron emission tomography was used as a comparative method to determine
tracer kinetics. Human radiation dose was assessed using OLINDA software.
Results: The radiochemical yield of [
18F]CFT from the initial [
18F]F
-, decay corrected to the end of bombardment,
was 3.2 ± 1.0%. The specific activity [SA] was 14.5 ± 3.4 GBq/μmol, decay corrected to the end of synthesis.
Radiochemical purity exceeded 99%. DAT-specific binding was found in the striatum, locus coeruleus, and
pancreas. NET-specific binding was found in the locus coeruleus. SERT-specific binding was not found in any of the
studied organs. Effective dose equivalent [EDE] estimated for the standard human model was 12.8 μSv/MBq.
Effective dose [ED] was 9.17 μSv/MBq.
Conclusions: Post-target-produced high-SA [
18F]F2 was used to incorporate
18F directly into the phenyl ring of [
18F]
CFT. The final product had high radiochemical and chemical purities and a high SA for DAT and NET studies in
vivo. In periphery, [
18F]CFT showed a specific uptake in the pancreas. EDE and ED corresponded well with other
18F-
radioligands.
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Background
Dopamine transporters [DAT] are proteins located in
the dopaminergic nerve terminals; they regulate the
synaptic concentration of dopamine in the brain.
Changes in the density and function of DAT in the
brain are involved in many neurodegenerative and neu-
ropsychiatric disorders, such as Parkinson’s disease and
schizophrenia. These changes can be imaged using posi-
tron emission tomography [PET].
Many radioligands, including [
11C]CFT [1] and several
[
18F]F-labeled phenyl tropane analogs of cocaine [2], have
been used to study dopamine reuptake in living subjects.
However, none of these fulfill the requirements for an
optimal radioligand for DAT imaging. [
11C]CFT suffers
from slow kinetics compared with the short half-life of
11C
(T1/2 = 20.4 min). The phenyl tropane analogs have a high
or moderate affinity with other monoamine transporters
(i.e., serotonin transporters [SERT] and norepinephrine
transporters [NET]), or they undergo extensive metabo-
lism. More recently, the new [
18F]F-labeled phenyl tropane
analog [
18F]FE-PE2I has shown promise as a radioligand
for DAT [3], despite its relatively fast metabolism [4].
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precursor, 2b-carbomethoxy-3b-(4-trimethylstannylphe-
nyl)tropane (precursor)t oa c h i e v e2 b-carbomethoxy-3b-
(4-[
18F]-fluorophenyl)tropane [[
18F]CFT] (product)( s e e
Figure 1) and preliminary evaluation of the radioligand
in rats were reported by Haaparanta et al. [5] and by
Bergman et al. [6]. A report on the ability of [
18F]CFT
to reflect nigral dopaminergic cell loss in a rat model of
Parkinson’s disease [7] as well as a study comparing the
brain accumulation, metabolism, and kinetics of [
18F]
CFT and [
18F]CFT-FP [8] have shown that [
18F]CFT can
be used to image DAT in rats. The suitability of [
18F]
CFT as a radioligand for in vivo studies of DAT in
humans has been evaluated [9], and [
18F]CFT has been
used in human studies of Parkinson’s disease [10-15],
schizophrenia [16,17], and detached personality [18].
[
18F]CFT was proven to be a suitable radiotracer to
image DAT by PET in humans due to its high target-to-
nontarget ratio and low metabolism [9] although [
3H]
CFT has also been shown to have some affinity to SERT
and NET [19,20]. The kinetics of [
18F]CFT are relatively
s l o w ,b u tt h eh a l f - l i f eo f
18F( T1/2 = 109.8 min) allows
equilibrium between specific and nonspecific binding
during a human PET study.
A PET radioligand suitable for DAT must have a mod-
erate to high specific activity [SA] to avoid saturation of
transporter sites (with associated pharmacological effects)
in patients. High SA can be easily achieved by nucleophi-
lic fluorination. The
18F label is usually incorporated into
a molecule via an alkyl side chain, as in the case of [
18F]
FE-PE2I [3] or [
18F]CFT-FP [21]. However, side chains
are often prone to fast metabolism. A more metabolically
stable configuration can be achieved by inserting
18F
directly into the phenyl ring via electrophilic fluorination.
[
18F]F2 is traditionally produced by either
20Ne(d,a)
18F
with an added F2 carrier [22] or
18O(p, n)
18F using
18O2/F2
as target [23]. The latter method is more efficient than
the former [24]. However, both production methods
suffer from low SA. Post-target-produced [
18F]F2 has
100- to 1,000-fold higher SA than the traditional meth-
ods [25]. Therefore, post-target-produced [
18F]F2 offers
the possibility of producing high-affinity radioligands
through electrophilic labeling.
In the present study, we report the optimized electro-
philic synthesis of [
18F]CFT with high SA and its quality
assurance for clinical PET studies. The pharmacological
specificity and selectivity of [
18F]CFT for monoamine
transporters ex vivo are reported. The distribution of
18F
activity in the brain and peripheral organs of rats is
reported ex vivo and in vivo in order to compare the
methods in the determination of tracer kinetics. The
human radiation dose is extrapolated from the animal
data using organ level internal dose assessment
[OLINDA]/EXM 1.0 software (OLINDA EXM, Vander-
bilt University, Nashville, TN, USA) [26].
Methods
Chemicals and equipment
The stannylated precursor and the reference compound,
2b-carbomethoxy-3b-(4-fluorophenyl)tropane, were sup-
plied by ABX (ABX GmbH, Radeberg, Germany). All
other reagents that were purchased from commercial
suppliers were either of synthesis grade or analytical
grade and were used without further purification.
Semi-preparative high-performance liquid chromato-
graphy [HPLC] was performed using a Merck-Hitachi
L-6200 HPLC pump (Merck AG, Darmstadt, Germany)
and a Waters μB o n d a p a kC 1 8c o l u m n( 7 . 8×3 0 0m m ,
10 μm; Waters Corporation, Milford, MA, USA). A
Merck-Hitachi L-7400 UV-absorption detector (l =2 1 5
nm) and a 2 × 2-in NaI crystal for
18F-activity detection
were used. The column was eluted with 0.01 M H3PO4/
CH3CN (7:3; flow rate of 3 ml/min).
Analytical HPLC was conducted using a Merck-Hitachi
L-7100 HPLC pump, an Atlantis dc18 column (5 μm;
Waters Corporation, Milford, MA, USA), a Merck-Hitachi
L-7400 UV-absorption detector (l = 215 nm) and a 2 × 2-
in NaI crystal for
18F-activity detection. The eluent used
was 0.01 M H3PO4/CH3CN (75:25; flow rate 1.1 ml/min).
Liquid chromatography/mass spectrometry [LC/MS]
was performed with a PE SCIEX API 150 EX mass spec-
trometer (PerkinElmer SCIEX, Toronto, Canada) equipped
w i t hat u r b oi o n - s p r a ys o u r c e ,aP e r k i n E l m e rs e r i e s2 0 0
micro pump (PerkinElmer Instruments, Branford, CT,
USA), and a Waters Symmetry C18 column (2.1 × 30 mm,
3.5 μm; Waters Corporation, Milford, MA, USA) were
used to measure the concentration of CFT. The column
was eluted with MeOH/0.2% HCOOH(aq) (flow rate
0.1 ml). A Supor Acrodisc (0.2 μm, 13 mm; Pall Corpora-
tion, NY, USA) sterile filter was used to formulate [
18F]
CFT for injection.
Production of [
18F]F
-
[
18F]F
- was obtained via the nuclear reaction
18O(p, n)
18F
by irradiating 700 μl
18O-enriched water with a 17-MeV
proton beam produced by an MGC-20 cyclotron (Efremov
N
CH3
COOCH3
Sn(CH3)3
H
H
N
CH3
COOCH3
F
18 H
H
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Figure 1 Scheme depicting the use of a stannylated precursor
to synthesize [
18F]CFT product.
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Russia).
Production of [
18F]F2
[
18F]F2 was synthesized in an electrical discharge cham-
ber by the
18F/
19F exchange reaction. The
18Fs o u r c ew a s
[
18F]fluoromethane, which was mixed with a low
amount (290 to 400 nmol) of carrier fluorine in neon
(Ne/0.5% F2) inside the discharge chamber. [
18F]Fluoro-
methane was produced from methyl iodide by a nucleo-
philic substitution reaction with a [
18F]F
-/Kryptofix
K2.2.2 complex in acetonitrile. A detailed description of
the [
18F]F2 synthesis is presented elsewhere [25].
Synthesis of [
18F]CFT
The stannylated precursor (precursor, 250 to 500 μg, 0.6
to 1.2 μmol) was dissolved in a mixture of trichloro-
fluoromethane (Freon-11, 600 μl) and dry acetic acid
(100 μl). [
18F]F2 was bubbled through this mixture at
room temperature. Freon-11 was evaporated using neon
flow, and 600 μl of preparative HPLC eluent was added
to the residue. With no further modifications, this solu-
tion was then loaded onto the preparative HPLC
column.
[
18F]CFT was purified by semi-preparative HPLC
using the system described in the ‘Chemicals and equip-
ment’ section. The 3-ml fraction containing the [
18F]
CFT was collected (Figure 2). The fraction was evapo-
rated to dryness with a vacuum evaporator, formulated
into a 0.9% NaCl/0.1 M phosphate buffer (phosphate
buffer pH 7, 3:2, v/v), and passed through the sterile fil-
ter into the end product vial.
Quality of [
18F]CFT
The
18F activity, pH, and volume were measured from the
end product. A sample from the end product was evalu-
ated by the analytical HPLC system described in the
‘Chemicals and equipment’ section. Determinations of
chemical purity, radiochemical purity [RCP], and SA
were conducted by comparing HPLC retention times and
peak intensities with a reference compound of known
concentration and
18F-activity concentration. Radioche-
mical yields [RCY] were calculated from the initial
amount of [
18F]F
- and decay corrected to the end of bom-
bardment [EOB]. The SA of the product was decay cor-
rected to the end of the semi-preparative HPLC
separation [EOS].
The SA of the final product was also determined with
L C / M Sb ym e a s u r i n gt h e[
19F]CFT mass concentration
using the same reference as was used with analytical
HPLC. The analyses were performed in positive selected
ion monitoring mode for m/z = 278 (corresponding to
the protonated molecule [MH
+]o f[
19F]CFT), and the
SAs are decay corrected to the EOS.
Animals
Sprague-Dawley rats (Harlan Sprague-Dawley, Indianapo-
lis, IN, USA) weighing 251 ± 59 g (15 females, 20 males)
were used in this study. The rats were housed under stan-
dard conditions (temperature 21°C; relative humidity 55 ±
5%; 12-h light/dark cycle) with free access to tap water
and standard food. Animal care was in accordance with
the guidelines of the International Council of Laboratory
Animal Science. The Turku University ethics committee
for animal experiments and the Animal Experiment Board
of the Province of Southern Finland approved this study.
Biodistribution studies
[
18F]CFT in 0.9% NaCl/0.1 M phosphate buffer (3:2, v/v,
pH 7) was injected into the tail vein of rats that are
sedated with CO2/O2 (50:50 vol.%). The
18F activity
injected via [
18F]CFT per rat was 57 ± 24 MBq (range,
12 to 181 MBq). This corresponds to a 23 ± 10-nmol/kg
(5 to 40 nmol/kg) administration of CFT, as calculated
from the SA that was determined using the HPLC method
at the time of injection. The animals were killed in a CO2
chamber at 10 min (n =2 ) ,2 0m i n( n =3 ) ,4 0m i n( n =6 ) ,
or 120 min (n = 3) after injection of the tracer. The brains
were rapidly removed, and a piece from the cerebellar cor-
tex of each brain was dissected, measured for
18F activity in
a calibrated 3 × 3-in NaI(Tl) well counter (Bicron, New-
bury, OH, USA), and weighed. After decay correction,
these data, expressed as the percentage of injected dose
per gram of tissue [%ID/g], were used to calibrate the
absolute uptake of
18F activity in autoradiographic brain
images. The rest of the brain was frozen in isopentane,
chilled with dry ice for sectioning with a cryomicrotome,
and handled as described in the ‘Digital autoradiography’
section.
Other organs and tissue samples were rapidly dis-
sected, weighed, and measured for
18F activity. The
decay-corrected uptake of
18F activity in the organs and
tissues was expressed as %ID/g.
Pharmacological studies
The specificity of [
18F]CFT binding to DAT in the brain in
pretreated rats was assessed with a selective DAT antago-
nist, GBR12909 (5 mg/kg, Sigma-RBI, St. Louis, MO,
USA). Selectivity was examined by injecting rats with a 5-
mg/kg dose of fluoxetine, a selective antagonist for SERT
(Sigma-RBI, St. Louis, MO, USA), or with a 5-mg/kg dose
of nisoxetine, a selective antagonist for NET (RBI, Natick,
MA, USA). Binding profiles of the antagonists are pre-
sented in Table 1. GBR12909, fluoxetine, or nisoxetine dis-
solved in distilled H2O/0.9% NaCl (50:50, v/v,2m g / m l )
were injected intravenously into rats 60 min prior to the
injection of [
18F]CFT. The rats were killed by CO2 inhala-
tion 40 min after injection of [
18F]CFT. The brains and
organs were handled as in the biodistribution studies. The
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Page 3 of 12regional distribution of
18F activity in the brains of control
rats (n = 6) and in the brains of rats that were pretreated
with GBR12909 (n = 7), fluoxetine (n = 6), or nisoxetine
(n = 6) were determined using digital autoradiography.
Digital autoradiography
Coronal brain sections (20 μm) were thaw-mounted
onto microscope slides, air dried, and apposed to an
imaging plate (Fuji Imaging Plate BAS-TR2025, Fuji
Photo Film Co., Ltd., Minato-ku, Tokyo, Japan) for 4 h.
The imaging plates were scanned with the Fuji Analyzer
BAS-5000.
The digital autoradiographic images were analyzed for
count density (photo-stimulated luminescence per unit
area [PSL/mm
2]) with a computerized image analysis
program (Tina 2.1, Raytest Isotopenmessgeräte, GmbH,
Straubenhardt, Germany). Regions of interest [ROIs]
were drawn over the frontal cortex, striatum, locus coer-
uleus, and cerebellum, which were anatomically identi-
fied from the cryomicrotome sections using a rat brain
atlas [27]. At least 10 sections were analyzed for each
brain region, and the count densities for background
areas were subtracted from the image data. PSL/mm
2
values were converted into %ID/g values as previously
described in the ‘Biodistribution studies’ section.
PET imaging
Two PET scans were carried out using an Inveon multi-
modality PET/computed tomography [CT] (Siemens
Medical Solutions, Knoxville, TN, USA) designed for
rodents and other small laboratory animals. The device
provides 159 transaxial slices, a 10.0-cm transaxial field
of view [FOV], and a 12.7-cm axial FOV. Rats were
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Figure 2 Sample chromatogram of a semi-preparative HPLC separation of [
18F]CFT from the reaction mixture.
Table 1 Binding profiles of the monoamine transporter
antagonist used in this study
Antagonist DAT SERT NET
CFT [37] 22.9 ± 0.4 100 ± 13 38.6 ± 9.9
GBR12909 [38] 10.6 ± 1.9
a 132 ± 0
b 496 ± 22
c
Fluoxetine [39] 3600 ± 100 0.81 ± 0.02 240 ± 10
Nisoxetine [40] 477 383 5.1
aHalf maximum inhibitory concentration [IC50] (nanomolar [nM]) of [
3H]CFT;
bIC50 (nM) of [
3H]citalopram;
cIC50 (nM) of [
3H]nisoxetine. DAT, dopamine
transporter; SERT, serotonin transporter; NET, norepinephrine transporter.
Values are Ki (nM) ± SEM, unless otherwise stated.
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Page 4 of 12anesthetized with 2% isoflurane approximately 15 min
before measurements. The body temperature of each rat
was maintained with a heating pad on which the rat lies.
Following the transmission scan for attenuation correc-
tion using the CT modality, an emission scan was
acquired for 120 min in three-dimensional [3-D] list
mode with an energy window of 350 to 650 keV. The
scans started immediately after intravenous injection of
[
18F]CFT (dose 27.9 MBq, mass 830 ng, SA 9.3 GBq/
μmol and dose 38.0 MBq, mass 1,200 ng, SA 8.8 GBq/
μmol at time of injection, respectively). List mode data
were stored in 3-D sinograms, which were then Fourier-
rebinned into two-dimensional [2-D] sinograms (45
frames with dimensions of 20 × 15 s, 15 × 600 s, 10 ×
600 s). The image was reconstructed using 2-D-filtered
back projection with a 0.5-mm RAMP filter. ROIs were
placed on the striatum, cerebellar cortex, frontal cortex,
and liver using the Inveon Research Workplace Image
Analysis software (Siemens Medical Solutions USA,
Knoxville, TN, USA) and with a CT template as an ana-
tomical reference.
Dosimetry
The animal %ID/g tissue data was extrapolated to
humans using the percentage kilogram per gram method
[28]. In this method, the animal %ID/g value is first mul-
tiplied with the animal’s weight and then multiplied with
the human organ weight/human weight ratio. Human
radiation dose was estimatedf r o mt h e s ev a l u e su s i n g
OLINDA/EXM 1.0 software [26].
Data analysis and statistical procedures
Statistical analyses were performed using the SPSS Statis-
tics 17.0 software (SPSS Inc., Chicago, IL, USA). Means
were considered significantly different when p <0 . 0 5 .
Comparison of SAs was tested using Student’s t test
(paired, two samples for mean assuming unequal
variances).
Effects of the pretreatments were tested using repeated
measurement analysis of variance. Results are expressed as
means ± SD for the indicated number of observations.
Results
Synthesis and quality of [
18F]CFT
Electrophilic fluorination was applied to a stannylated pre-
cursor (Figure 1) to synthesize [
18F]CFT product (n = 24).
The initial [
18F]F
- activity was 37 ± 3 GBq (range, 32 to 42
GBq), and the average synthesis time was 43 ± 3 min,
including the synthesis of [
18F]F2,r a d i o f l u o r i n a t i o n ,a n d
semi-preparative purification. In a semi-preparative HPLC
purification, the [
18F]CFT fraction eluting at 10.5 min was
collected (Figure 2). Evaporation to dryness and formula-
tion for injection took an additional 10 min.
The RCY calculated from initial [
18F]F
- (decay cor-
rected to EOB) was 3.2 ± 1.0%, and
18F activity of [
18F]
CFT was 917 ± 278 MBq (501 to 1,395 MBq) at EOS.
The SA measured by analytical HPLC was 14.5 ± 3.4
GBq/μmol (8.9 to 23.6 GBq/μmol with all values decay
corrected to EOS). From analytical HPLC studies (Figure
3), the RCP exceeded 99% in all cases. The pH of the
final product was 7. The final product was radiochemi-
cally stable for up to 6 h.
From selected batches (n = 19), the SA of the final pro-
duct was determined by LC/MS. The SA of these batches
measured by analytical HPLC was 14.9 ± 3.1 GBq/μmol.
The SA measured by LC/MS was 18.2 ± 5.9 GBq/μmol.
SAs calculated using the analytical HPLC method differed
significantly from the SAs calculated using the LC/MS
method (p = 0.04).
Biodistribution and pharmacological studies
The
18F-activity accumulation in the striatum, locus coeru-
leus, frontal cortex, and cerebellum of control rats and
monoamine inhibitor-pretreated rats 40 min after [
18F]
CFT injection is presented in Table 2. Pretreatment with
GBR12909 significantly reduced the [
18F]CFT uptake in
the striatum (p = 0.006) and locus coeruleus (p = 0.02). In
nisoxetine-pretreated rats, the [
18F]CFT uptake decreased
significantly in the locus coeruleus (p < 0.005). Fluoxetine
pretreatment had no effect on the accumulation of the
18F
activity in any region studied. Autoradiograms of repre-
sentative brain sections from a control rat and from rats
pretreated with GBR12909, fluoxetine, or nisoxetine are
shown in Figure 4.
The region-to-cerebellum ratios at different time points
from the ex vivo and in vivo s t u d i e sa r es h o w ni nF i g u r e
5a,b, respectively. In ex vivo studies, the striatum-to-cere-
bellum ratio increased from 2.1 ± 0.2 at 10 min to 8.8 ±
2.2 at 120 min. The locus coeruleus-to-cerebellum ratio
was 2.2 ± 0.3 at 10 min and 3.5 ± 1.6 at 120 min. The
frontal cortex-to-cerebellum ratio was constant, ranging
from 1.4 to 1.6 at all time points and with all pretreat-
ments. All monoamine inhibitors used in this study signifi-
cantly decreased the locus coeruleus-to-cerebellum ratio.
Pretreatment with GBR12909 significantly reduced the
striatum-to-cerebellum ratio.
The
18F-activity accumulation in the peripheral organs
and tissues after the injection of [
18F]CFT is presented
in Table 3. The accumulation of [
18F]CFT-derived
18F
activity peaked at 20 min in most tissues and decreased
thereafter (Figure 6). High levels of
18Fa c t i v i t yw e r e
recorded in the liver, kidneys, and spleen. In the liver,
the highest uptake (8.3 ± 1.2% ID/g) was measured 120
min after injection of [
18F]CFT.
18F-activity accumulation
in the bone increased slowly with time, but it was still
low (0.19 ± 0.15% ID/g) at 120 min.
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decreased the uptake of
18F activity in the pancreas
(p = 0.03). No significant changes in the
18F-activity uptake
were recorded in the periphery of the rats pretreated with
nisoxetine or fluoxetine.
PET imaging
The in vivo distribution and uptake of
18F activity after
[
18F]CFT injection in the brain of rats are presented in
F i g u r e7 .T h eu p t a k eo f
18F activity in the striatum and
cerebellum peaked during the first 5 to 10 min and
decreased thereafter. The striatum-to-cerebellum ratio
reached the maximum value of approximately 9 at
60 min. The time courses of the striatum-to-cortex and
cortex-to-cerebellum ratios are shown in Figure 5b. The
highest in vivo uptake of
18F activity in the periphery was
observed in the liver. The uptake increased in the liver
during the first 60 min of PET imaging and was almost
constant until the end of the scanning (i.e., until
120 min after injection).
Dosimetry
The effective dose equivalent [EDE] estimated for the
standard human model was 12.8 μSv/MBq. Effective
dose [ED] was 9.17 μSv/MBq.
Discussion
Post-target-produced [
18F]F2 [25] offers a feasible
method to produce PET tracers with high SA for neu-
roimaging through electrophilic fluorination. When
using post-target-produced [
18F]F2,t h eS Ad e p e n d so n
several factors, such as the initial amount of [
18F]F
- and
the amount of carrier fluorine used in the
19F-
18F
exchange reaction [25]. The SA of [
18F]CFT can poten-
tially be increased by further optimizing this
19F-
18F
exchange reaction by decreasing the amount of carrier
F2. However, in our hands, this resulted in a dramatic
decrease in RCY. The amount of carrier F2 used in this
study (290 to 400 nmol) is a compromise, offering SA
0123456
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Figure 3 Sample chromatogram of radio-HPLC analysis of formulated [
18F]CFT.
Table 2
18F-activity uptake 40 min after injection of [
18F]
CFT into the brains of control and pretreated rats
Brain region Control
n =6
GBR12909
n =7
Nisoxetine
n =6
Fluoxetine
n =6
Striatum 1.55 ± 0.78 0.49 ± 0.18* 1.48 ± 0.22 1.38 ± 0.75
Locus coeruleus 0.67 ± 0.29 0.37 ± 0.11** 0.23 ± 0.05* 0.47 ± 0.16
Frontal cortex 0.32 ± 0.08 0.23 ± 0.04 0.26 ± 0.03 0.33 ± 0.13
Cerebellum 0.20 ± 0.04 0.15 ± 0.04 0.17 ± 0.02 0.23 ± 0.09
*p < 0.01 compared with control;**p < 0.05 compared with control. Uptake
values are in percent injected dose per gram tissue. All values are means ±
SD. The effect of pretreatment was compared with the uptake values of
control rats. Means were considered significantly different when p < 0.05.
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studies from one production run. The radiochemical
and chemical purities of the final product were verified
by HPLC, and both were found to fulfill the require-
ments for human injection (i.e., RCP > 95.0% and the
absence of unknown signals in the UV trace; Figure 3).
Signals from compounds other than CFT observed in
the UV trace were from the formulation solution.
For radioligands having very high SA, the sensitivity
limitation of UV detection means that LC/MS can be
the only method to determine the SA [29]. In the
present case where [
18F]CFT is synthesized through
electrophilic fluorination at high SA, we therefore com-
pared the HPLC/UV absorption and the LC/MS techni-
que for the determination of SA. In quantitative
analyses, LC/MS is a faster and more sensitive method
than HPLC combined with a UV detector. However,
LC/MS is more easily affected by changes in the sample
matrix. In this study, the SAs were significantly higher
when determined by the LC/MS method than by the
HPLC method (i.e., the concentration of CFT was lower
when measured by LC/MS than by HPLC). This could
 
Control 
Pretreated with DAT 
inhibitor GBR 12909 
Pretreated with SERT 
inhibitor Fluoxetine 
Pretreated with NET 
inhibitor Nisoxetine 
Striatum  Cortex 
Cerebellum 
Locus Coeruleus 
Figure 4 Representative [
18F]CFT autoradiographic images. Brain slices from control rats and from rats pretreated with GBR12909, fluoxetine,
or nisoxetine.
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Page 7 of 12be due to ion suppression in LC/MS [30]. The effect of
ion suppression could be diminished by more extensive
chromatographic separation or sample preparation prior
to MS. However, both methods of analysis are suitable
for analysis in the present case.
In the biodistribution study, the highest level of
18F
activity was found in the main excretory organs.
Additionally, the uptake in the bone was low even at
120 min, reflecting the good stability of the carbon-
fluorine bond.
18F activity accumulated in the liver with
the highest value at 120 min, indicating slow excretion
and low metabolism. In all other organs studied, the
18F
activity peaked 20 min after injection (see Table 3). The
results from the in vivo study were in accordance with
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Figure 5 The time courses of the brain region-to-cerebellum ratios. They are from the ex vivo study after [
18F]CFT injection where n =2t o
4/time point (a) and from the in vivo animal PET study where n =2( b).
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Page 8 of 12the ex vivo findings. [
18F]CFT has been reported to be
relatively resistant to metabolism; in a microdialysis
study of 120 min in rodents, the amount of unmetabo-
lized [
18F]CFT was approximately 64% of the total
18F
activity [31].
In the periphery, non-neuronal DAT expression and
DAT immunoreactivity have been found in the stomach,
pancreas, and kidneys [32]. [
18F]CFT uptake in the pan-
creas, stomach, and kidneys was moderate in the present
study. After GBR12909 pretreatment, the
18F-activity
uptake decreased significantly in the pancreas, indicating
DAT-specific binding. In this study, no NET- or SERT-
specific binding of
18F activity was found in the periphery
even though extraneuronal NET expression has been
found in the lungs, adrenal medulla, and placenta [32].
In the brain, the accumulation of
18F activity in the stria-
tum was specific for DAT; it was significantly decreased
with GBR12909 pretreatment (Figure 4). In addition to
DAT, the striatum contains a low density of SERT, and
NET is virtually absent [33]. Neither fluoxetine nor
Table 3
18F-activity uptake after injection of [
18F]CFT in the organs of control and pretreated rats
Organ 10 min
n =2
20 min
n =3
40 min
n =4
120 min
n =3
GBR12909
n =3
Nisoxetine
n =3
Fluoxetine
n =2
Blood 0.06 ± 0.03 0.07 ± 0.01 0.05 ± 0.02 0.03 ± 0.01 0.04 ± 0.01 0.06 ± 0.01 0.03 ± 0.02
Liver 0.65 ± 0.45 5.17 ± 1.99 4.90 ± 3.74 8.26 ± 1.16 3.38 ± 0.94 5.86 ± 0.10 4.22 ± 1.22
Adrenal gland 0.28 ± 0.14 0.36 ± 0.01 0.24 ± 0.03 0.17 ± 0.06 0.23 ± 0.07 0.25 ± 0.02 0.24 ± 0.11
Spleen 0.36 ± 0.24 0.88 ± 0.28 0.49 ± 0.05 0.26 ± 0.13 0.50 ± 0.19 0.44 ± 0.07 0.44 ± 0.02
Pancreas 0.28 ± 0.10 0.53 ± 0.04 0.35 ± 0.11 0.16 ± 0.01 0.17 ± 0.05* 0.31 ± 0.02 0.22 ± 0.12
Kidney 0.72 ± 0.16 0.91 ± 0.11 0.66 ± 0.31 0.28 ± 0.07 0.53 ± 0.13 0.47 ± 0.02 0.41 ± 0.18
Stomach 0.12 ± 0.09 0.53 ± 0.38 0.19 ± 0.05 0.08 ± 0.05 0.47 ± 0.37 0.11 ± 0.01 0.17
Lung 0.51 ± 0.37 0.46 ± 0.07 0.29 ± 0.08 0.17 ± 0.06 0.20 ± 0.05 0.25 ± 0.01 0.25 ± 0.04
Heart 0.14 ± 0.06 0.16 ± 0.03 0.11 ± 0.02 0.07 ± 0.02 0.10 ± 0.03 0.11 ± 0.01 0.13 ± 0.02
Muscle 0.07 ± 0.02 0.15 ± 0.03 0.09 ± 0.03 0.05 ± 0.01 0.08 ± 0.02 0.10 ± 0.01 0.07 ± 0.03
Urinary bladder 0.14 ± 0.14 0.51 ± 0.23 0.31 ± 0.13 0.24 ± 0.13 0.30 ± 0.12 0.28 ± 0.01 0.22 ± 0.04
Bone 0.03 ± 0.01 0.09 ± 0.02 0.07 ± 0.04 0.19 ± 0.15 0.06 ± 0.01 0.31 ± 0.20 0.09 ± 0.04
Marrow 0.22 ± 0.16 0.63 ± 0.17 0.47 ± 0.10 0.20 ± 0.05 0.39 ± 0.12 0.49 ± 0.05 0.40 ± 0.04
Fat, subcutaneous 0.03 ± 0.01 0.06 ± 0.01 0.07 ± 0.03 0.03 ± 0.01 0.04 ± 0.02 0.07 ± 0.01 0.05 ± 0.03
*p < 0.05 compared to 40 min. Uptakes (percent injected dose per gram tissue) occurred in the organs of control rats at different time points and in organs of
pretreated rats at 40 min. All values are means ± SD. The effect of pretreatment was compared with the uptake values of control rats at 40 min. Means were
considered significantly different when p < 0.05.
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Page 9 of 12nisoxetine pretreatment affected the
18F-activity uptake in
the striatum. High
18F-activity accumulation was seen in
the locus coeruleus, a brain region with high NET density
as has been earlier shown by Burchett et al. [34]. A similar
finding in monkeys using [
3H]CFT was observed by Kauf-
man and Madras [19]. The
18F-activity accumulation in
locus coeruleus was significantly decreased in rats pre-
treated with nisoxetine, which indicates that NET sites also
bind with [
18F]CFT. Because NET is virtually absent in the
striatum, [
18F]CFT is suitable for imaging striatal DAT
sites. However, the accumulation of
18F activity in locus
coeruleus was also significantly decreased in rats pretreated
with GBR12909. The affinity of CFT for DAT and NET is
of the same order of magnitude (Table 1). With the rela-
tively high dose of GBR12909 used in the pretreatment of
the animals, it is evident that although the affinity of
GBR12909 for NET is 50-fold less than for DAT, this
dosage is high enough to displace [
18F]CFT from the NET
s i t e si nt h el o c u sc o e r u l e u s .I ti sn o t e w o r t h yt h a tt h ep
value in the statistical analyses is higher for the locus coer-
uleus than for the striatum in the GBR12909 blocking
study.
In the ex vivo study, the uptake ratios for the striatum,
locus coeruleus, and cortex versus the cerebellum
reached a maximum between 40 and 120 min. In the in
vivo study, the maximum striatum-to-cerebellum ratio
was reached at 60 min. In both studies, the absolute
values for this ratio were similar in the range of 9 to 10.
It is noteworthy that due to its small size, the locus
c o e r u l e u sc a n n o tb ea n a l y z e df r o mt h ein vivo PET
study. These parallel studies provide a good demonstra-
tion of the strengths and weaknesses of different meth-
ods in radiopharmacological studies. Overall, the
distribution of
18F activity in rats after [
18F]CFT injection
was in good agreement with our earlier preliminary stu-
dies [5,8] and with studies using [
3H]CFT [19,35].
Figure 7 Animal PET-CT image of [
18F]CFT accumulation in the brain of rats. Data were collected for 2 to 120 min post injection.
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18F]CFT are
9.17 μSv/MBq and 12.8 μSv/MBq, respectively, and they
a r ei nl i n ew i t ht h o s eo fa n o t h e rd o p a m i n et r a n s p o r t e r
ligand,
18F-FPCIT [36]. Extrapolation of the animal data to
humans to estimate the human radiation dose is inexact,
but the order of magnitude of the EDE and ED values for
[
18F]CFT correspond well with those of other
18F-labeled
radioligands.
Conclusions
Post-target-produced high-SA [
18F]F2 was used to incor-
porate
18F directly into the phenyl ring of [
18F]CFT. The
final product had high radiochemical and chemical puri-
ties and a high SA for neurotransmitter studies in vivo.
It is noteworthy that as [
18F]CFT shows a specific bind-
ing to NET in addition to DAT, [
18F]CFT can also be
used for imaging NET. The finding that [
18F]CFT shows
specific uptake in the pancreas also warrants future stu-
dies in humans with respect to potential utility in pan-
creatic imaging.
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